[
  {
    "ts": "2025-11-24T12:45:00+00:00",
    "headline": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
    "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
    "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1d8d0747-1d94-3b4e-9c56-5bb146867a46",
      "content": {
        "id": "1d8d0747-1d94-3b4e-9c56-5bb146867a46",
        "contentType": "STORY",
        "title": "RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum",
        "description": "",
        "summary": "RVL Pharmaceuticals, Inc and its affiliates (together, \"RVL\") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.",
        "pubDate": "2025-11-24T12:45:00Z",
        "displayTime": "2025-11-24T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rc80fgTAsLDaU9xn4TeSqQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VZWM2VsT7coc_hFN.xjnzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80efeb6a95ce099da2d60c9bf9629f50.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rvl-pharmaceuticals-announces-leadership-appointments-124500429.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVLPQ"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-24T12:00:00+00:00",
    "headline": "Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)",
    "summary": "NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b",
    "url": "https://finance.yahoo.com/news/arvinas-announces-data-presentations-vepdegestrant-120000255.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ab841ed7-137e-3a59-83b7-3eff8b5c40b6",
      "content": {
        "id": "ab841ed7-137e-3a59-83b7-3eff8b5c40b6",
        "contentType": "STORY",
        "title": "Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)",
        "description": "",
        "summary": "NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b",
        "pubDate": "2025-11-24T12:00:00Z",
        "displayTime": "2025-11-24T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081",
          "originalWidth": 696,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yh2mtJa2t7nTvrtnMIWuQQ--~B/aD0yNTI7dz02OTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081.cf.webp",
              "width": 696,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGbLsZv8o._cDdc.ul0VDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/92323019a5a4213cf6ded7f6af366081.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/arvinas-announces-data-presentations-vepdegestrant-120000255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/arvinas-announces-data-presentations-vepdegestrant-120000255.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARVN"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]